Chen CH - Search Results

1

EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.

Yamaguchi H, Du Y, Nakai K, Ding M, Chang SS, Hsu JL, Yao J, Wei Y, Nie L, Jiao S, Chang WC, Chen CH, Yu Y, Hortobagyi GN, Hung MC. Yamaguchi H, et al. Among authors: chen ch. Oncogene. 2018 Jan 11;37(2):208-217. doi: 10.1038/onc.2017.311. Epub 2017 Sep 18. Oncogene. 2018. PMID: 28925391 Free PMC article.

2

Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.

Ko CJ, Lan SW, Lu YC, Cheng TS, Lai PF, Tsai CH, Hsu TW, Lin HY, Shyu HY, Wu SR, Lin HH, Hsiao PW, Chen CH, Huang HP, Lee MS. Ko CJ, et al. Among authors: chen ch. Oncogene. 2017 Aug 10;36(32):4597-4609. doi: 10.1038/onc.2017.82. Epub 2017 Apr 3. Oncogene. 2017. PMID: 28368394

3

HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms.

Chen CH, Chang WH, Su KY, Ku WH, Chang GC, Hong QS, Hsiao YJ, Chen HC, Chen HY, Wu R, Yang PC, Chen JJ, Yu SL. Chen CH, et al. Among authors: chen jj, chen hy, chen hc. Oncogene. 2016 Oct 27;35(43):5674-5685. doi: 10.1038/onc.2016.106. Epub 2016 Apr 11. Oncogene. 2016. PMID: 27065329

4

Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.

Chen CH, Fong LWR, Yu E, Wu R, Trott JF, Weiss RH. Chen CH, et al. Oncogene. 2017 Jun 22;36(25):3588-3598. doi: 10.1038/onc.2016.510. Epub 2017 Feb 6. Oncogene. 2017. PMID: 28166200 Free PMC article.

5

Reduced door-to-balloon times in acute ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.

Wang YC, Lo PH, Chang SS, Lin JJ, Wang HJ, Chang CP, Hsieh LC, Chen YP, Chen WK, Chen CH, Chang KC, Hung JS. Wang YC, et al. Among authors: chen wk, chen ch, chen yp. Int J Clin Pract. 2012 Jan;66(1):69-76. doi: 10.1111/j.1742-1241.2011.02775.x. Int J Clin Pract. 2012. PMID: 22171906

6

Rictor regulates cell migration by suppressing RhoGDI2.

Agarwal NK, Chen CH, Cho H, Boulbès DR, Spooner E, Sarbassov DD. Agarwal NK, et al. Among authors: chen ch. Oncogene. 2013 May 16;32(20):2521-6. doi: 10.1038/onc.2012.287. Epub 2012 Jul 9. Oncogene. 2013. PMID: 22777355 Free PMC article.

7

Integrity of mTORC2 is dependent on the rictor Gly-934 site.

Aimbetov R, Chen CH, Bulgakova O, Abetov D, Bissenbaev AK, Bersimbaev RI, Sarbassov DD. Aimbetov R, et al. Among authors: chen ch. Oncogene. 2012 Apr 19;31(16):2115-20. doi: 10.1038/onc.2011.404. Epub 2011 Sep 12. Oncogene. 2012. PMID: 21909137 Free PMC article.

8

A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis.

Chen CH, Thai P, Yoneda K, Adler KB, Yang PC, Wu R. Chen CH, et al. Oncogene. 2014 Jul 10;33(28):3696-706. doi: 10.1038/onc.2013.336. Epub 2013 Aug 19. Oncogene. 2014. PMID: 23955080 Free PMC article.

9

Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity.

Chen CH, Chien CY, Huang CC, Hwang CF, Chuang HC, Fang FM, Huang HY, Chen CM, Liu HL, Huang CY. Chen CH, et al. Among authors: chen cm. Oncogene. 2009 Jul 30;28(30):2723-37. doi: 10.1038/onc.2009.128. Epub 2009 Jun 15. Oncogene. 2009. PMID: 19525975

10

FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway.

Chen CH, Lu PJ, Chen YC, Fu SL, Wu KJ, Tsou AP, Lee YC, Lin TC, Hsu SL, Lin WJ, Huang CY, Chou CK. Chen CH, et al. Among authors: chen yc. Oncogene. 2007 Jun 21;26(29):4272-83. doi: 10.1038/sj.onc.1210207. Epub 2007 Jan 22. Oncogene. 2007. PMID: 17237822

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8,801 results

Search Page